scispace - formally typeset
V

Vladimir Tesar

Researcher at First Faculty of Medicine, Charles University in Prague

Publications -  307
Citations -  22066

Vladimir Tesar is an academic researcher from First Faculty of Medicine, Charles University in Prague. The author has contributed to research in topics: Medicine & Kidney disease. The author has an hindex of 48, co-authored 256 publications receiving 17061 citations. Previous affiliations of Vladimir Tesar include Charles University in Prague.

Papers
More filters
Journal ArticleDOI

Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.

TL;DR: The International Mycophenolate Mofetil Protocol to Reduce Outbreaks of Vasculitides (IMPROVE) trial as mentioned in this paper was conducted at 42 centers in 11 European countries between 2002 and 2009 (42-month study).
Journal ArticleDOI

Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens

Krzysztof Kiryluk, +91 more
- 01 Nov 2014 - 
TL;DR: A genome-wide association study of IgA nephropathy (IgAN), the most common form of glomerulonephritis, with discovery and follow-up in 20,612 individuals of European and East Asian ancestry is performed, suggesting a possible role for host–intestinal pathogen interactions in shaping the genetic landscape of IgAN.
Journal ArticleDOI

Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis

TL;DR: Among patients with severe ANCA-associated vasculitis, the use of plasma exchange did not reduce the incidence of death or ESKD, and a reduced-dose regimen of glucocorticoids was noninferior to a standard- dose regimen with respect to death orESKD.
Journal ArticleDOI

2019 Update of the Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis

TL;DR: The EULAR recommendations for the management of LN are updated to facilitate homogenization of patient care and transplantation is the preferred kidney replacement option with immunosuppression guided by transplant protocols and/or extra-renal manifestations.